CLINICAL EFFECTIVENESS OF ANTRAL IN PATIENTS WITH CHRONIC PANCREATITIS
Authors: Khukhina O. S. , Dudka I. V. , Dudka T. V. , Smandych V. S. 
Published: July 2020

The studies on the pathogenesis of chronic pancreatitis (CP) have proven the important role of systemic inflammation, factors of proteinase-inhibitory system with increasing damaging effects of systemic proteolysis, disturbance of oxidant-antioxidant homeostasis, changes in blood lipid and protein spectroscopic processes that collectively contribute to inhibition of reparative processes and the activation of pancreatic fibrosis processes. The aim of this study was to determine the effectiveness of applying Antral medicine in the treatment of CP in the exacerbation phase on the basis of a comprehensive assessment of clinical course of CP and structural and functional disorders of the pancreas. Material and methods. 52 patients with CP of mixed aetiology were examined in the exacerbation phase of moderate severity. The first group (group 1, control) included 24 people, who received standard treatment within 30 days. The main group (group 2) involved 28 people, who in addition to the standard therapy took Antral (Pharmak OAO, Kyiv) in a dose of 1 tablet (200 mg) 3 times a day for 30 days. The comparison group consisted of 30 healthy individuals of the same age and sex. Results. In 4 weeks since the beginning of the therapy, the astheno-vegetative syndrome was found as significantly less manifested in only 2 people (7.1%) of the 2 groups, whereas in the 1 group it remained in 17 patients. At the same time in all patients of group 2 (100.0%) the pain and feeling of heaviness in the epigastric region, pain in the left and right subcostal area were disappeared, they did not complain of nausea.

The restoration of physical performance in 100.0% of patients in the 2 group can be regarded as a positive manifestation of the therapy efficacy. Analyzing the indicators, which characterize the phase of CP exacerbation, it is necessary to note the patients of the 2 group demonstrated higher efficacy of their treatment program. Thus, dynamic indicators of blood α-amylase activity against the background of hyperfermentemia diagnosed prior the treatment and in the phase of CP exacerbation significantly decreased in both groups of observation on the 30th day of the therapy; the syndrome of enzyme rejection in the blood was eliminated in 100% of patients of the 2 groups; whereas in group 1 this was observed only in 58.3% of the patients. The dynamic of indicators of the inflammation syndrome in patients with CP (by blood C-reactive protein content) indicates its complete elimination in 96.4% of the patients in group 2 vs. 29.2% of the patients in group 1. Analysis of the dynamic indicators of elastase-1 content in the faeces of the patients with CP on the 30th day of the therapy indicates a significant increase in this indicator in only group 2. Restoration of the secretory capacity of the pancreas was observed in 78.6% of patients in group 2 vs. 20.8% of the patients in group 1. Conclusions. Complex therapy of patients with chronic pancreatitis with applying Antral in addition to the integrated therapy has led to faster, when compared with only standard therapy, achieving clinical remission of chronic pancreatitis, elimination of inflammatory pancreatic oedema, hyperfermentemia and inflammation, restoration of the external secretion of the pancreas.